Why Esperion Just Ghosted Wall Street

For context, the business was already doing $263 million in revenue through just nine months of 2024. Hitting $350 million in full-year 2027 sales isn't some fantasy; it's a reasonable trajectory if growth continues at even a fraction of recent rates.

Why Go Private Now?

Esperion's situation is a textbook case of the "public market penalty." When you're a small-cap biotech that spent years disappointing investors, every quarter becomes a referendum on your existence. Analysts had a $16 price target from H.C. Wainwright, yet the stock couldn't break $4. The disconnect between the business reality and market perception had become a prison.

Going private lets ARCHIMED do what public market investors wouldn't: be patient. They can reinvest in the commercial launch without worrying about quarterly EPS. They can expand the Daiichi Sankyo partnership (which already covers Europe, Asia, and Latin America) without explaining the short-term margin impact to analysts on an earnings call.

The deal also reflects a broader industry pattern. Biopharma M&A reached $292.55 billion in 2025. Nearly one quarter of biotech acquisitions last year used CVRs to bridge valuation gaps, exactly the structure ARCHIMED chose here.

The Bigger Picture: Small Biotechs Are Fleeing Public Markets

Esperion isn't alone. Smaller biopharma companies are finding public life increasingly inhospitable. The IPO window has been mostly shut; only three biopharma IPOs priced in Q1 2026, raising $1.7 billion total. Follow-on financings are tough. Investor patience is thin.

Private equity firms see opportunity in this mismatch. They can buy commercial-stage businesses at depressed public valuations, strip out the overhead of being a public company, and run them for cash flow. It's like buying a profitable restaurant that happens to have terrible Yelp reviews: the food is good, the customers are coming back, but the narrative is broken.

For Esperion specifically, the Daiichi Sankyo partnership provides a built-in growth engine. A 2024 amendment worth $125 million expanded the collaboration to include potential triple-combination products. The franchise is approved in 39 countries.

What Happens Next

The deal needs shareholder approval and regulatory clearance under the Hart-Scott-Rodino Act. Closing is expected in Q3 2026, at which point Esperion will delist from Nasdaq.

Debt financing comes from Pharmakon Advisors, and importantly, the transaction has no financing condition. Translation: the money is committed. This isn't one of those deals that falls apart because the buyer can't get a loan.

For long-suffering Esperion shareholders, this is bittersweet. A 58% premium sounds great until you remember the stock was above $100 seven years ago. But for the company itself, going private might be exactly what it needs. Sometimes the best move for a business that's finally working is to stop performing for an audience that stopped watching.

Gilead Just Walked Away From a $1 Billion Bet on Cancer

Gilead Sciences is unwinding its once-massive oncology alliance with Arcus Biosciences after key lung cancer trials hit a futility wall. With over a billion dollars already invested and a string of recent acquisitions reshaping its cancer strategy, this breakup says as much about where oncology is heading as where it's been.